PlantForm Releases White Paper: Recommendations for an Effective COVID-19 Testing Strategy
GUELPH, Ontario, Canada, April 23, 2020—PlantForm Corporation has published a white paper with recommendations for an effective COVID-19 testing strategy, including the need to implement a large-scale serological analysis for SARS-CoV-2 antibodies.
Much of the impact of the coronavirus pandemic "can be mitigated by a better understanding of the epidemiology of viral spread and a better ability to identify those who are susceptible to COVID-19, those who are infected, and those who have recovered," the white paper states.
Read Recommendations for an Effective COVID-19 Testing Strategy: A White Paper on the Need to Implement a Large-Scale Serological Analysis for SARS-CoV-2 Antibodies.
Learn more about PlantForm initiatives to respond to COVID-19 testing and treatment needs.
About PlantForm Corporation
PlantForm Corporation is a biopharmaceutical company focused on the rapid development and production of biosimilar and specialty antibodies and proteins using the company’s proprietary vivoXPRESS® platform. The plant-based vivoXPRESS® system makes it easier, faster and less expensive to produce biologics for approved and novel indications. The technology platform originated at the University of Guelph through the work of Chris Hall as one of the company’s founders. PlantForm has an expanding portfolio of patents in seven families to protect both the core platform technology and products in development.
For more information, please contact:
President and CEO
Stacey Curry Gunn
Director of Communications